Mountain View, CA, October 3, 2004
IMPAC Medical Systems,
Inc. (NASDAQ:IMPCE), a leading provider of information technology
solutions for oncology care announced today the introduction of
ANALYTIQ™, IMPAC’s line of data aggregation, analysis, and
reporting tools. ANALYTIQ provides valuable solutions that enable
cancer care providers and researchers to mine information compiled
by IMPAC’s oncology IT solutions. With ANALYTIQ, IMPAC provides
the cancer care team with a powerful and flexible means for data
analysis and discovery.
“The intersection of diagnostic, treatment, and follow-up data
within the ANALYTIQ database provides limitless possibilities for
outcomes reporting and benchmarking,” said Joseph K. Jachinowski,
president and CEO of IMPAC Medical Systems, Inc. “ANALYTIQ
unleashes the powerful information collected by IMPAC’s spectrum
of cancer care products. By providing opportunities to tap into
this valuable information, IMPAC ultimately helps practices plan
for expansion, substantiate performance, and refine clinical
practices to improve patient care.”
The introductory module of the ANALYTIQ line is ANALYTIQ Practice,
a set of visualizations that effectively and efficiently mine
financial and utilization data from IMPAC’s practice management
system to facilitate analysis of financial performance,
productivity, and utilization. Demonstrations of this product are
available at IMPAC Booth # 1744 during the annual meeting of the
American Society for Therapeutic Radiology and Oncology in
Atlanta, Georgia, October
3-6, 2004.
About IMPAC Medical Systems
IMPAC Medical Systems, Inc. is a leading provider of oncology IT
solutions that streamline both clinical and business operations to
help improve the process of delivering quality patient care. With
systems designed for anatomic pathology, medical oncology,
radiation oncology, imaging, clinical laboratory, and cancer
registry, IMPAC supports the entire team of healthcare
professionals who contribute to the care of the cancer patient.
Supporting more than 2500 installations worldwide, IMPAC provides
practical solutions that deliver better overall communication,
process efficiency and quality patient care. For more information
about ANALYTIQ or other IMPAC products, please call 888-GO-IMPAC
or visit www.impac.com.
The statements contained in this press
release that are not purely historical are forward looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, including statements regarding the Company's
expectations, beliefs, hopes, intentions or strategies regarding
the future. Forward looking statements include statements
regarding the Company's review of its revenue recognition policies
and the estimated impact of the proposed financial restatement of
previously report results, possible delisting from The NASDAQ
Stock Market, business strategy, timing of, and plans for, the
introduction of new products and enhancements, future sales,
market growth and direction, competition, market share, revenue
growth, operating margins and profitability. All forward looking
statements included in this document are based upon information
available to the Company as of the date hereof, and the Company
assumes no obligation to update any such forward looking
statement. Actual results could differ materially from the
Company's current expectations. Factors that could cause or
contribute to such differences include the Company's ability to
expand outside the radiation oncology market or expand into
international markets, our inability to recognize revenue from
multiple element software contracts where certain elements have
been delivered, installed and accepted but other elements remain
undelivered, lost sales or lower sales prices due to competitive
pressures, the ability to integrate its products successfully with
related products and systems in the medical services industry,
reliance on distributors and manufacturers of oncology equipment
to market its products, changes in Medicare reimbursement
policies, the integration and performance of acquired businesses,
and other factors and risks discussed in the 10 K/A and other
reports filed by the Company from time to time with the Securities
and Exchange Commission. |
